Linagliptin and Metformin HCl

Strengths:

• 2.5 mg + 500 mg
• 2.5 mg + 850 mg
• 2.5 mg + 1000 mg

Dosage Form: Tablets

Description:

This combination enhances glycemic control by combining the DPP-4 inhibitor Linagliptin with Metformin, which improves insulin sensitivity and reduces glucose production.

Key Features:

• Dual mechanism of action
• Low risk of hypoglycemia
• Weight-neutral and cardiovascular-friendly profile

Precautions:

• Monitor renal function periodically
• Risk of lactic acidosis with Metformin
• Avoid excessive alcohol intake